ArticleDiscover oncology2025
MiRNA-21 promotes the migration and proliferation of prostate cancer cells via activating the JAK/STAT pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal urinary biomarker panel achieves superior prostate cancer detection accuracy and reduces unnecessary biopsies.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research explored the role of microRNA (miRNA)-21 in prostate cancer (PCa) cells, as well as its regulation of the JAK/STAT pathway in PCa cells. Quantitative real-time PCR was employed to examine miRNA-21 expression in PCa cells. Cell viability and proliferation were detected by MTT and colony formation assays. Cell migration was measured by wound healing and transwell assays. The janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway-related protein expression was detected using western blot. The results indicated that miRNA-21 was significantly up-regulated in PCa cells, and inhibition of miRNA-21 suppressed the viability, proliferation and migration of PCa cells. Besides, inhibition of miRNA-21 lessened the levels of JAK/STAT pathway-related proteins in both PCa cells. Additionally, Ruxolitinib treatment (an inhibitor of the JAK/STAT pathway) could reverse the elevated cell viability and proliferation in miRNA-21 mimics-transfected PCa cells. Taken together, our study demonstrates that miRNA-21 promotes the migration and proliferation of PCa cells via activating the JAK /STAT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.